Premium
Activity of Eight Fluoroquinolones against Both Methicillin‐Susceptible and ‐Resistant Staphylococcus aureus Isolated from Skin Infections
Author(s) -
Nishijima Setsuko,
Namura Shoko,
Akamatsu Hirohiko,
Kawai Shuzou,
Asada Yasuo,
Kawabata Shigekatsu,
Fujita Maasa
Publication year - 1995
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1995.tb03362.x
Subject(s) - staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , skin infection , medicine , biology , bacteria , genetics
The in vitro susceptibility of Staphylococcus aureus to eight fluoroquinolones, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, and nadifloxacin was established by agar dilution tests, 71 isolates of methicillin‐susceptible (MSSA) and 74 isolates of ‐resistant S. aureus (MRSA) isolated from skin infections. Among all of the fluoroquinolones, nadifloxacin exhibited the lowest MIC for both MSSA and MRSA. In addition, there were no resistant S. aureus , neither MSSA and MRSA, to nadifloxacin. With the exception of nadifloxacin, the incidence of MRSA resistant to fluoroquinolones has gradually increased in recent years. Over half of the MRSA strains were resistant to norfloxacin, ofloxacin, enoxacin, ciprofloxacin, and lomefloxacin.